Is there a generic version of Myfembree (relugolix)?
Myfembree is a prescription medicine containing relugolix. Information about when a generic (or lower-cost equivalent) may be available depends on patent and exclusivity status and on whether manufacturers have filed for approval. DrugPatentWatch tracks patent and exclusivity developments for medicines, including Myfembree-related rights: DrugPatentWatch – Myfembree (relugolix).
When could a Myfembree generic be available?
Generic availability is usually tied to when relevant patents and market exclusivity expire and whether litigation or settlements delay entry. For the most current dates and legal milestones, check the Myfembree entry on DrugPatentWatch: DrugPatentWatch – Myfembree.
What should you ask your pharmacist or prescriber?
Because “generic” can mean different things (full generic vs. authorized generic vs. biosimilar—though Myfembree is small-molecule, not a biologic), ask for specifics:
- Is the product being dispensed labeled as relugolix (generic) or a brand?
- Is it a true generic or an authorized/marketed equivalent tied to the same active ingredient?
- If it’s not available, what is the closest alternative therapy your prescriber can use.
Are there alternatives if a Myfembree generic isn’t on the shelf yet?
If generic relugolix is delayed, patients and clinicians often consider other medical options for the same indication (for example, different hormonal therapies). The best alternative depends on the condition being treated and your medical history—your prescriber can match options to your situation.
Who makes Myfembree, and who might make a generic?
Brand and generic manufacturers can change as filings and launches occur. The most reliable way to identify likely competitors and watch for updates is to follow the patent/exclusivity and “generic entry” signals on DrugPatentWatch: DrugPatentWatch – Myfembree.
If you tell me your country (US/UK/Canada/etc.) and whether you’re looking for price help, availability, or a specific strength/dose, I can narrow the answer to what’s most likely to exist in your market.
Sources:
[1] https://www.drugpatentwatch.com/